Handelsbanken Fonder AB Buys Shares of 12,700 Disc Medicine, Inc. $IRON
Handelsbanken Fonder AB has acquired 12,700 shares of Disc Medicine, Inc. (NASDAQ:IRON) valued at approximately $929,000, as revealed in its latest SEC filing. This acquisition is part of broader institutional investor activity, with institutional ownership now at 83.70%. Despite some insider selling, analysts maintain a "Moderate Buy" rating for Disc Medicine, with a consensus target price of $106.50, and the company recently reported a narrower-than-expected quarterly loss.
Disc Medicine CEO John Quisel sells $2.6m in shares
Disc Medicine CEO John D. Quisel sold 33,000 shares of the company's common stock for over $2.6 million on August 17, 2026, as part of a pre-arranged trading plan. Concurrently, he exercised options to acquire an equal number of shares. This follows recent positive clinical trial data and regulatory alignment for Disc Medicine's investigational treatments, leading to reiterated "Overweight" and "Buy" ratings from analysts, despite an InvestingPro analysis suggesting the stock is overvalued.
Disc Medicine Investor News: If You Have Suffered Losses in
The Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) after its stock price fell 22% due to a U.S. Food and Drug Administration Complete Response Letter regarding its bitopertin program. Shareholders who suffered losses are encouraged to contact the firm to potentially join a class action lawsuit. The firm highlights its experience in securities class actions and successful recovery of investor losses.
Insider Selling: Disc Medicine (NASDAQ:IRON) CEO Sells 33,000 Shares of Stock
Disc Medicine (NASDAQ:IRON) CEO John Quisel sold 33,000 shares of company stock for approximately $2.61 million, reducing his direct ownership by 12.74%. Despite this insider selling, the stock rose 0.2% to $80.20, and the company reported a smaller-than-expected quarterly loss. Analysts maintain a "Moderate Buy" consensus with an average target price of $106.50, and institutional investors hold a significant 83.7% of the stock.
Disc Medicine (IRON) CEO sells 33K shares under trading plan
Disc Medicine, Inc. (IRON) CEO John D. Quisel exercised options for 33,000 shares at $13.50 per share and subsequently sold all 33,000 shares in three open-market transactions on August 17, 2026. The sales were executed at weighted average prices between $78.1061 and $79.8420 per share, totaling approximately $2.61 million in gross proceeds. These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan established on March 12, 2026.
Disc Medicine CEO John D. Quisel disposes of USD 2.63 million in common shares
Disc Medicine CEO John D. Quisel exercised options for 33,000 shares on August 17, 2026, at $13.5 per share. The same day, he sold these 33,000 shares for approximately $2.63 million, with weighted-average prices ranging from $78.11 to $79.84. Following these transactions, his direct holdings of common stock decreased to 226,064 shares, and stock options held dropped to 91,586.
GSA Capital Partners LLP Takes $1.19 Million Position in Disc Medicine, Inc. $IRON
GSA Capital Partners LLP has acquired a new position in Disc Medicine, Inc. (NASDAQ:IRON), purchasing 16,324 shares valued at approximately $1.19 million in the second quarter. This move aligns with a broader trend of institutional investment, as other funds like Handelsbanken Fonder AB and Bank of America Corp DE have also increased their stakes. Despite recent insider selling totaling over $8 million, analysts maintain a "Moderate Buy" consensus rating with an average price target of $106.50 for Disc Medicine.
Disc Medicine faces class action after FDA rejects drug application, causing stock to drop 22%.
Disc Medicine is facing a class action lawsuit after the FDA issued a Complete Response Letter rejecting its new drug application for bitopertin, citing a need for more evidence. This news led to a 22% drop in the company's stock. The Rosen Law Firm is investigating potential securities claims and preparing a lawsuit to recover investor losses.
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
The Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) after the FDA issued a Complete Response Letter for its bitopertin program, causing a 22% stock drop. The firm encourages investors who purchased Disc Medicine securities to inquire about joining a prospective class action to recover losses.
Disc Medicine Investor News: If You Have Suffered Losses in
The Rosen Law Firm is investigating potential securities claims on behalf of Disc Medicine, Inc. (NASDAQ: IRON) shareholders due to allegations of materially misleading business information. This follows a 22% stock price drop on February 13, 2026, after the FDA issued a Complete Response Letter for Disc Medicine's bitopertin program, citing uncertainties. Investors who purchased Disc Medicine securities are encouraged to contact the firm regarding a prospective class action to recover losses.
Disc Medicine COO Jonathan Yu sells $66,444 in shares By Investing.com
Disc Medicine COO Jonathan Yu recently sold 804 shares of the company's common stock for $66,444 at a weighted average price of $82.6425, pursuant to a pre-arranged trading plan. On the same day, he acquired 804 shares through stock option exercises at $13.5 per share. Following these transactions, Yu directly holds 54,324 shares and beneficially owns 22,943 derivative securities.
Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
The Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) after the FDA issued a Complete Response Letter for its bitopertin program, causing a 22% stock price drop. Investors who suffered losses are encouraged to contact the firm for a potential class action lawsuit. The firm highlights its track record in securities class actions and encourages affected investors to seek qualified counsel.
Disc Medicine COO Jonathan Yu sells $66,444 in shares
Disc Medicine COO Jonathan Yu recently sold 804 shares of the company's common stock for $66,444, executed under a Rule 10b5-1 trading plan. On the same day, he acquired 804 shares through stock option exercises for $10,854. Following these transactions, Yu holds 54,324 shares and 22,943 derivative securities.
Insider Selling: Disc Medicine (NASDAQ:IRON) COO Sells 804 Shares
Disc Medicine (NASDAQ:IRON) COO Jonathan Yen-Wen Yu recently sold 804 shares of the company's stock for $66,442.56, reducing his total holdings by 1.46%. This sale is part of a series of insider transactions since mid-June. Despite these sales, the company exceeded its recent quarterly earnings expectations and maintains a "Moderate Buy" consensus rating from analysts with a target price of $106.00.
Disc Medicine COO Jonathan Yu sells $66,444 in shares
Jonathan Yen-Wen Yu, COO of Disc Medicine Inc. (NASDAQ:IRON), sold 804 shares of company stock for $66,444 on August 12, 2026, as part of a pre-arranged trading plan. On the same day, Yu acquired 804 shares through stock option exercises for $10,854. These transactions come amidst recent positive clinical trial updates and reiterated "Overweight" and "Buy" ratings from analysts for Disc Medicine.
Disc Medicine (NASDAQ: IRON) COO trades 804 shares via 10b5-1 plan
Disc Medicine's COO, Yu Jonathan Yen-Wen, exercised stock options for 804 shares at $13.50 each and simultaneously sold these 804 shares at a weighted average price of $82.6425. These transactions, which generated an approximate pre-tax spread of $56,000, were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 17, 2026. Following these transactions, the COO still holds 22,943 option shares from the same grant, which vest monthly and expire in December 2032.
Disc Medicine COO Jonathan Yu sells $66,444 in shares By Investing.com
Disc Medicine's COO, Jonathan Yu, sold 804 shares of the company's common stock for a total of $66,444 at an average price of $82.6425. This transaction was part of a pre-arranged trading plan, and it occurred as the stock had seen a 41% return over the past six months. Yu also acquired 804 shares through stock option exercises for $10,854, increasing his direct holdings to 54,324 shares.
Sei Investments Co. Takes Position in Disc Medicine, Inc. $IRON
Sei Investments Co. has initiated a new position in Disc Medicine, Inc. (NASDAQ:IRON), purchasing 15,510 shares valued at approximately $992,000. Institutional investors now collectively own 83.70% of the company, while insiders have recently sold over 110,000 shares worth around $8 million. Disc Medicine exceeded quarterly earnings expectations, and analysts maintain a "Moderate Buy" rating with an average price target of $106.00, compared to its current share price of $80.59.
Renaissance Technologies LLC Sells 31,000 Shares of Disc Medicine, Inc. $IRON
Renaissance Technologies LLC reduced its stake in Disc Medicine, Inc. (NASDAQ:IRON) by 49.3% in the first quarter, selling 31,000 shares and retaining 31,820 shares worth approximately $2.035 million. Despite this sale, other institutional investors increased their holdings, and company insiders sold over 110,000 shares in the last three months. Disc Medicine recently reported better-than-expected quarterly earnings and has an average "Moderate Buy" rating from analysts with a consensus target price of $106.00.
The Manufacturers Life Insurance Company Decreases Stock Position in Disc Medicine, Inc. $IRON
The Manufacturers Life Insurance Company reduced its stake in Disc Medicine, Inc. by 38.1% in the first quarter, selling 20,017 shares and retaining 32,493 shares valued at approximately $2.1 million. This comes amidst significant insider selling, including by CEO John D. Quisel, and an ongoing investigation into potential securities claims against the company. Despite these concerns, analyst sentiment remains largely positive with a "Moderate Buy" rating and an average price target of $106.
Disc Medicine, Inc. $IRON Shares Sold by Assenagon Asset Management S.A.
Assenagon Asset Management S.A. decreased its stake in Disc Medicine, Inc. by 29.7% in the second quarter, selling 162,089 shares and retaining 384,158 shares valued at $28.1 million. Despite insider sales totaling nearly $8.0 million and an ongoing investigation by Rosen Law Firm, analysts maintain a "Moderate Buy" consensus with an average price target of $106, significantly higher than its current trading price of $77.44. The company reported a narrower-than-expected quarterly loss of $1.54 per share, beating the consensus estimate of $1.71.
HC Wainwright Decreases Earnings Estimates for Disc Medicine
HC Wainwright has lowered its Q3 2026 earnings estimate for Disc Medicine (NASDAQ:IRON) to a loss of $1.71 per share, from a previous forecast of $1.70, while maintaining a "Buy" rating and a $120 price target. Despite the lowered estimates, the company recently reported a Q3 loss of $1.54 per share, beating the consensus estimate by $0.17. Analyst sentiment remains generally positive, with a "Moderate Buy" consensus rating and an average price target of $106, although insiders have recently sold shares.
Disc Medicine Investor News: If You Have Suffered Losses in
The Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) after the FDA issued a Complete Response Letter for its bitopertin program, causing a 22% stock drop. Investors who suffered losses are encouraged to contact the firm regarding a prospective class action for recovery of their losses. The firm highlights its experience and success in securities class action litigation.
Disc Medicine Chief Legal Officer Rahul Khara disposes of 5,000 common shares for $400,000
Disc Medicine's Chief Legal Officer, Rahul Khara, sold 5,000 common shares for $400,000 on August 6, following the exercise of 5,000 stock options. After these transactions, Khara directly held 52,324 shares and 49,804 stock options. This information was generated by AI from an SEC filing.
Disc Medicine Insider Sold Shares Worth $400,000, According to a Recent SEC Filing
An insider at Disc Medicine recently sold company shares valued at $400,000, as disclosed in a recent SEC filing. The transaction indicates a significant insider sale, which could be of interest to investors monitoring the company's stock. Further details would typically be available in the SEC filing itself.
Disc Medicine (NASDAQ:IRON) Insider Rahul Khara Sells 5,000 Shares
Disc Medicine insider Rahul Khara sold 5,000 shares of the company's stock for $400,000, reducing his direct ownership by 8.72% to 52,324 shares. The company recently reported a quarterly loss of $1.54 per share, beating analyst expectations, and has a "Moderate Buy" consensus rating with an average price target of $106.00. Institutional investors hold approximately 83.7% of the company's stock.
Rahul Khara, Disc Medicine CLO, sells $400,000 in shares
Rahul Khara, Chief Legal Officer at Disc Medicine Inc. (IRON), sold 5,000 shares worth $400,000 on August 6, 2026, while also acquiring 5,000 shares through stock option exercise for $73,450. These transactions were part of a Rule 10b5-1 trading plan. Following these sales, Khara directly holds 52,324 shares and beneficially owns additional derivative securities.
Disc Medicine (NASDAQ: IRON) CLO sells 5,000 shares after option exercise
Disc Medicine, Inc.'s Chief Legal Officer, Rahul Khara, exercised 5,000 stock options at $14.69 per share and subsequently sold 5,000 common shares at $80.00 per share on August 6, 2026. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 19, 2026. Following these transactions, Khara retains 49,804 unexercised options and 52,324 common shares.
IRON (IRON) filer plans 5,000-share stock sale after option exercise
An IRON insider has filed a Form 144 notice to sell 5,000 shares of common stock, valued at $394,550.00, on August 6, 2026. This sale follows the exercise of stock options for cash on the same date. The filing also details previous Rule 10b5-1 sales by Rahul Khara, totaling 10,000 shares over three transactions in June 2026.
H.C. Wainwright Maintains Disc Medicine(IRON.US) With Buy Rating, Announces Target Price $120
H.C. Wainwright has reiterated its Buy rating on Disc Medicine (IRON.US) and set a target price of $120. This indicates a strong positive outlook from the firm regarding the company's stock performance.
Disc Medicine (IRON): FMR LLC, Abigail Johnson report 12.8% ownership of common stock
FMR LLC and Abigail P. Johnson have reported an updated beneficial ownership of 12.8% of Disc Medicine Inc. (IRON) common stock, totaling 4,875,472.97 shares, through an Amendment No. 4 to a Schedule 13G filing. FMR LLC holds sole voting power over 4,875,263 shares and sole dispositive power over all 4,875,472.97 shares, while Abigail P. Johnson has sole dispositive power over the same amount but no voting power. The filing confirms that other persons may receive dividends or sale proceeds, but none hold more than a 5% interest individually.
HC Wainwright Forecasts Strong Price Appreciation for Disc Medicine (NASDAQ:IRON) Stock
HC Wainwright has increased its price target for Disc Medicine (NASDAQ:IRON) to $120 from $118, maintaining a "Buy" rating and suggesting a 52% upside. Analyst sentiment is generally positive, with a consensus "Moderate Buy" rating and an average target of $106. Despite beating quarterly EPS expectations, insiders have sold over 105,000 shares worth approximately $7.6 million in the last three months.
Dimensional Fund Advisors LP Raises Holdings in Disc Medicine, Inc. $IRON
Dimensional Fund Advisors LP significantly increased its stake in Disc Medicine, Inc. (NASDAQ:IRON) by 76.4% in the first quarter, now holding 394,447 shares valued at $25.2 million. Despite insider selling totaling $7.6 million, institutional investors collectively own 83.7% of the company. Analysts maintain a "Moderate Buy" rating with a consensus price target of $104.44 for Disc Medicine.
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
The Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) after the FDA issued a Complete Response Letter for its bitopertin program, causing a 22% stock drop. Investors who purchased Disc Medicine securities may be entitled to compensation and are encouraged to contact the firm for information on joining a class action lawsuit.
Disc Medicine Investor News: If You Have Suffered Losses in
The Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) after the FDA issued a Complete Response Letter regarding its bitopertin program, causing a 22% stock price drop. Investors who suffered losses are encouraged to contact the firm to learn about joining a prospective class action for compensation. The firm highlights its experience and success in securities class action litigation.
Disc Medicine, Inc. Revenue Breakdown – NASDAQ:IRON
The article provides a financial overview of Disc Medicine, Inc. (NASDAQ:IRON) on TradingView, focusing on its revenue breakdown and other fundamental statistics. It highlights sections for statements, dividends, earnings, and segment performance. The content indicates that the market was closed at the time of viewing, with no trades reported.
Disc Medicine, Inc. (IRON) Stock Analysis: Exploring a 32% Potential Upside with Strong Buy Ratings
Disc Medicine, Inc. (NASDAQ: IRON) is a clinical-stage biopharmaceutical company focused on developing therapies for hematologic diseases. Analysts project a 32% potential upside for the stock, with an average target price of $101.00 and 13 strong buy ratings. Despite negative earnings and cash flow, typical for a developmental biotech, the company's innovative pipeline and R&D focus position it for long-term growth, though investors should acknowledge the inherent risks in the sector.
How Investors Are Reacting To Disc Medicine (IRON) Balancing Larger Losses With APOLLO Phase 3 FDA Alignment
Disc Medicine (IRON) reported a widening net loss in Q2 2026 but investors are focusing on clinical and regulatory milestones, particularly the FDA alignment for its bitopertin APOLLO Phase 3 trial. The company's investment narrative centers on its iron homeostasis platform converting late-stage clinical assets into commercial products, with bitopertin being a core value driver despite rising losses and financial uncertainties. The article emphasizes that while the stock might be undervalued, potential investors should consider the financial risks and regulatory dependence on the APOLLO trial.
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
The Rosen Law Firm is investigating potential securities claims on behalf of Disc Medicine, Inc. (NASDAQ: IRON) shareholders following allegations of materially misleading business information. This investigation stems from the FDA's Complete Response Letter regarding Disc Medicine's bitopertin program, which caused the stock price to fall by 22% on February 13, 2026. Investors who purchased Disc Medicine securities are encouraged to join the prospective class action.
How Investors Are Reacting To Disc Medicine (IRON) Balancing Larger Losses With APOLLO Phase 3 FDA Alignment
Disc Medicine (IRON) reported widening losses in Q2 2026 but saw its stock rise due to alignment with the FDA on the bitopertin APOLLO Phase 3 trial. The company's investment narrative focuses on converting clinical assets into commercial products, with bitopertin as a core value driver despite financial risks. Investors are weighing the potential of clinical and regulatory milestones against rising losses and future funding needs.
TD Cowen Maintains Disc Medicine(IRON.US) With Buy Rating
TD Cowen has reiterated its Buy rating on Disc Medicine (IRON.US). The article does not provide specific details on the rationale behind this rating or any new price target.
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
The Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) following a 22% stock price drop on February 13, 2026. This decline occurred after the FDA issued a Complete Response Letter for Disc Medicine's bitopertin program, citing uncertainties in the new drug application. Investors who purchased Disc Medicine securities may be entitled to compensation through a class action lawsuit.
Disc Medicine reports Q2 net loss of $59.5M, cash of $717.7M; APOLLO topline due Q4 2026
Disc Medicine reported a Q2 2026 net loss of $59.5 million, an increase from $55.2 million in Q2 2025, and ended the quarter with $717.7 million in cash, expected to fund operations into 2029. The company anticipates topline results from its Phase 3 APOLLO study in Q4 2026 and expects several other clinical readouts in the second half of 2026, including initial data for DISC-3405 in polycythemia vera and sickle cell disease. Disc Medicine also highlighted positive Phase 2 data for selcodebart and regulatory milestones for bitopertin and selcodebart.
Disc Medicine Expects to Submit CRL Response and Receive FDA Decision by Mid-2027 >IRON
Disc Medicine announced expectations to submit its Complete Response Letter (CRL) response to the FDA by mid-2027. This follows the FDA's request for additional preclinical data for their drug candidate, which the company aims to provide within the specified timeframe. The company anticipates receiving the FDA's decision on the resubmission by mid-2027.
Disc Medicine (NASDAQ:IRON) Releases Earnings Results, Beats Estimates By $0.17 EPS
Disc Medicine (NASDAQ:IRON) reported its quarterly earnings, announcing a loss of $1.54 per share, which beat analysts' estimates by $0.17. Following the announcement, the company's shares increased by 7.5% to $79.21, pushing its market capitalization to approximately $3.02 billion. Analysts maintain a "Moderate Buy" rating for IRON with an average price target of $104.44, despite recent insider stock sales totaling about $7.6 million.
Disc Medicine 2Q 2026: Net loss $(59.5M), EPS $(1.54) — 10-Q Summary
Disc Medicine, Inc. reported a net loss of $(59.5M) for Q2 2026, slightly higher than $(55.2M) in the prior year, with a diluted loss per share of $(1.54). The company holds $717.7M in cash and equivalents, supporting ongoing late-stage trials for bitopertin and selcodebart, with key topline data expected in Q4 2026 for the APOLLO trial. A prior Complete Response Letter (CRL) from the FDA for bitopertin cited uncertainty regarding clinical benefit, which a successful APOLLO trial could address.
Disc Medicine launches expanded access to bitopertin before FDA decision
Disc Medicine reported a net loss of $59.5 million in Q2 2026, but maintains a strong cash position of $717.7 million, expected to fund operations into 2029. The company launched an Expanded Access Program for bitopertin for eligible EPP/XLP patients, with topline APOLLO study data anticipated in Q4 2026 and an FDA decision by mid-2027. Significant advancements are also expected across its pipeline, including selcodebart and DISC-3405.
Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update
Disc Medicine announced its second-quarter 2026 financial results, highlighting a strong cash position of $717.7 million, funding operations into 2029. Key clinical development updates include anticipated topline data for the Phase 3 APOLLO trial of bitopertin in EPP in Q4 2026, completion of enrollment for the RESTORE-PV Phase 2 study of DISC-3405, and positive clinical data from the RALLY-MF Phase 2 trial of selcodebart in anemia of myelofibrosis. The company also launched an Expanded Access Program for bitopertin and expects significant advancements across its pipeline in the second half of 2026.
Disc Medicine (IRON) to Post Quarterly Earnings on Thursday
Disc Medicine (NASDAQ:IRON) is scheduled to post its Q2 2026 earnings before market open on Thursday, August 6th, with analysts expecting a loss of ($1.7125) per share and $1.00 million in revenue. The company recently reported a Q1 earnings miss and has seen recent insider selling by its COO and another insider. Wall Street analysts currently have a "Moderate Buy" consensus rating for the stock with a consensus price target of $104.44.
ETFs Investing in Disc Medicine, Inc. Stocks
This article lists various Exchange Traded Funds (ETFs) that hold shares of Disc Medicine, Inc. (IRON), providing details such as market value, weight in the ETF, issuer, management style, and expense ratio. The ETFs primarily focus on biotechnology, small-cap, and extended market sectors, offering investors diversified exposure to Disc Medicine, Inc.
